Drug Trial Radar · NCT05384938
FAsenra Safety Trial in India
Last checked: Nov 20, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Nov 19, 2021
Primary completion
Jul 1, 2023
Study completion Jul 1, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Benralizumab is a humanised, afucosylated, monoclonal antibody that binds specifically to the human interlukin-5 (IL-5) receptor alpha subunit (IL-5Rα) of target cells such as eosinophils and basophils (Takatsu et al, 1994; Toba et al, 1999; Pelaia et al, 2020). Benralizumab was generally well tolerated by patients in clinical trials, with no apparent safety concerns. This study shall be conducted at 10 centers across India. The primary outcome measures will be * Percentage of AEs a, SAEs, and TEAEs * Nature, incidence, and severity of AEs including unexpected adverse drug reactions * Percentage of patients with AEs that lead to study treatment discontinuations.
Conditions
- In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
Interventions
BenralizumabBiological
Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEsTime frame: From study treatment to follow-up (up to 24 weeks)
- Severity of AEsTime frame: From study treatment to follow-up (up to 24 weeks)
- Participants With AEs That Led to Study Treatment Discontinuations or ModificationsTime frame: From study treatment to follow-up (up to 24 weeks)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Bengaluru, India
Research Site
Chennai, India
Research Site
Delhi, India
Research Site
Hyderabad, India
Research Site
Jaipur, India
Research Site
Jodhpur, India
Research Site
Lucknow, India
Research Site
Mumbai, India
Research Site
New Delhi, India
Research Site
Noida, India
Research Site
Noida, India
Research Site
Noida, India
Research Site
Visakhapatnam, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.